Clark Capital Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

Clark Capital Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-44,194	Closed	-$2.03M	–	333
2016 Q3	$2.03M	Buy	+44,194	New	+$2.31M	0.12%	171
2016 Q2	–	Sell	-38,705	Closed	-$2.07M	–	353
2016 Q1	$2.07M	Sell	38,705 -98,669	-72%	-$5.79M	0.16%	154
2015 Q4	$9.02M	Buy	137,374 +46,785	+52%	+$2.89M	0.73%	38
2015 Q3	$5.12M	Buy	90,589 +7,040	+8%	+$456K	0.46%	70
2015 Q2	$4.94M	Buy	83,549 +63,757	+322%	+$3.93M	0.45%	67
2015 Q1	$1.23M	Buy	19,792 +3,817	+24%	+$222K	0.11%	155
2014 Q4	$919K	Buy	15,975 +2,708	+20%	+$151K	0.08%	145
2014 Q3	$713K	Buy	13,267 +2,461	+23%	+$130K	0.06%	154
2014 Q2	$566K	Buy	+10,806	New	+$552K	0.05%	187
2013 Q4	–	Sell	-10,341	Closed	-$391K	–	378
2013 Q3	$391K	Sell	10,341 -230	-2%	-$8.97K	0.03%	230
2013 Q2	$414K	Buy	+10,571	New	+$412K	0.04%	212

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Clark Capital Management Group's TEVA Position: Q4 2016 in Review

Clark Capital Management Group sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 44,194 shares — an estimated $2.03M sold.

Clark Capital Management Group first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $9.02M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Clark Capital Management Group reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Clark Capital Management Group sold 44,194 Teva Pharmaceuticals shares in Q4 2016, an estimated $2.03M.
Clark Capital Management Group first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Clark Capital Management Group's Teva Pharmaceuticals position peaked at $9.02M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Clark Capital Management Group's 13F filing for Q4 2016, filed 8 Feb 2017.